Why OS Therapies Incorporated’s (OSTX) Stock Is Down 5.52%
As of Tuesday, October 13, OS Therapies Incorporated’s OSTX share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Commentary & Analysis
Why OS Therapies Incorporated’s (OSTX) Stock Is Up 6.88%
As of Tuesday, October 06, OS Therapies Incorporated’s OSTX share price has surged by 6.88%, which has investors questioning if this is right time to sell.Michael Rose
Why OS Therapies Incorporated’s (OSTX) Stock Is Down 5.37%
As of Wednesday, September 23, OS Therapies Incorporated’s OSTX share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Michael Rose
Why OS Therapies Incorporated’s (OSTX) Stock Is Up 5.17%
As of Tuesday, September 22, OS Therapies Incorporated’s OSTX share price has surged by 5.17%, which has investors questioning if this is right time to sell.Michael Rose
Why OS Therapies Incorporated’s (OSTX) Stock Is Up 11.14%
As of Thursday, September 17, OS Therapies Incorporated’s OSTX share price has surged by 11.14%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | OSTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $58.7 | $228.7 | 18% |
|
| Shares Out (Mil) | 43.9 | 53.9 | 45% |
|
| Institutional Ownership | 34.5% | 92.9% | 15% |
|
| Float (Mil) | 40.4 | 42.1 | 42% |
|
| Beta | -0.73 | 0.95 | 2% |
|
| Avg Daily Volume (000s) | 490 | 574 | 58% |
|
| Price Change (52-week) |
(30.6%) | 47.3% | 30% |
|
| Growth | OSTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (36.9%) | (10.1%) | 11% |
|
| EPS (5yr) | (6.5%) | 15.8% | 24 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.2%) | (15.7%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.120) | ($0.700) | $0.347 | |
| Month Ago EPS | ($0.120) | ($0.700) | $0.347 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.197) | ($0.777) | $0.360 | |
| Year/Year Chg | (39.1%) | (28.8%) | (178.3%) | |
| Financials | OSTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($39) | ($44) | 18% |
|
| EPS (TTM) | ($1.053) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($33) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $74 | $177 | 19% |
|
| Valuation | OSTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.24 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OSTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (389.6%) | (47.0%) | 1% |
|
| ROE | na | (54.1%) | na |
|
| Liabilities to Assets | 209.6% | 29.1% | 99% |
|
| F-Score | 1 | 2 | 1% |
|
OS Therapies Incorporated did not pass any screens on 10/21/2026.
